Full-Time

Toxicology Senior Research Fellow

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$229.6k - $344.4k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible: work remotely up to two days per week; or work five days per week on-site with ad hoc flexibility.

Category
Lab & Research
Medical Research
Required Skills
Data Analysis
Requirements
  • Subject matter expertise in toxicology and the design and interpretation of in vivo studies in common preclinical species
  • In-depth knowledge of animal husbandry and animal welfare issues
  • Excellent data processing and statistical skills
  • Excellent written, verbal communications and influencing skills
  • Microsoft Office Suite or equivalent office productivity tools
  • Bachelor’s, Master’s or Doctoral degree in life sciences or chemistry
  • Bachelors degree and 20 years experience or
  • Masters degree and 15 years experience or
  • PhD and 11 years experience
Responsibilities
  • Develops a broad and deep understanding of the disease area, target biology and chemical space for all Research programs at their resident site
  • Independently develops the strategy for early safety assessment and support for multiple programs from target selection to the VXc milestone and aligns with PSA leadership
  • Collaborates with cross-functional and cross-site partners to develop safety strategies tailored to the portfolio at their resident site
  • Acts as a liaison between the project teams and other PSA subfunctions to arrange required studies and profiling assays and communicates results to the project team and site management with appropriate interpretation
  • Works with PSA study monitors to provide scientific oversight of external studies at CROs/partner organizations and communicates significant findings and study events to supervisors and PSA leadership in a timely manner
  • Collaborates closely with the program regulatory toxicologists to ensure a smooth transition into development at the VXc milestone
  • Prepares high quality reports and presentations to clearly communicate study plans and results to peers, management and project teams
  • Keeps up to date with current literature and emerging industry trends in general pharmaceutical toxicology and therapeutics
  • Acts as an opinion leader and mentor to other toxicologists and cross-disciplinary research scientists
Desired Qualifications
  • DABT certification preferred
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approval for expanded cystic fibrosis treatment label boosts market penetration in Europe.
  • Partnership with Arbor Biotechnologies positions Vertex at the forefront of innovative treatments.
  • Recent investments indicate strong investor confidence in Vertex's growth potential.

What critics are saying

  • Recent layoffs suggest financial or strategic challenges impacting operational capabilities.
  • Discontinuation of diabetes asset indicates difficulty diversifying beyond cystic fibrosis.
  • Reliance on key products like ivacaftor makes Vertex vulnerable to market fluctuations.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's collaboration with Arbor Biotechnologies advances novel ex vivo engineered cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Pharmalive
Jun 11th, 2025
After axing diabetes asset, Vertex lays off 140 staff

After axing diabetes asset, Vertex lays off 140 staff.

PBN
Jun 10th, 2025
Vertex Pharmaceuticals to lay off 125 R.I. employees

PROVIDENCE - Vertex Pharmaceuticals Inc. is laying off 125 people in Rhode Island, according to a WARN notice filed with the R.I. Department of Labor and Training on June 8.

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.